Subutex is a prescription medication used to treat opioid dependence in adults. Its active ingredient, buprenorphine, reduces withdrawal symptoms and cravings, helping people stop using opioids like heroin, fentanyl, or prescription painkillers. The FDA approved it in 2002, and while the brand name was discontinued in 2011 for business reasons (not safety concerns), generic buprenorphine sublingual tablets remain widely available and work the same way.
Subutex is always meant to be part of a broader treatment plan that includes counseling and behavioral therapy. The medication handles the physical side of dependence while therapy addresses the patterns and triggers behind it.
How Buprenorphine Works in the Brain
Opioids like heroin and fentanyl flood the brain’s opioid receptors, producing intense highs followed by painful withdrawal. Buprenorphine takes a different approach. It binds to those same receptors but only partially activates them, producing enough of a response to ease withdrawal and cravings without delivering the full euphoric effect of stronger opioids.
This partial activation comes with a built-in safety feature called a ceiling effect. After a certain dose, taking more buprenorphine doesn’t increase its effects on breathing the way heroin or fentanyl would. That ceiling on respiratory depression is a major reason buprenorphine carries a lower overdose risk than full opioids. For pain relief, however, buprenorphine behaves more like a full opioid, needing only a small fraction of receptors (roughly 5 to 10 percent) to produce meaningful pain control.
Buprenorphine also grips opioid receptors tightly and releases slowly. This means it can block other opioids from attaching to those receptors, which discourages misuse. If someone takes heroin while on a stable buprenorphine dose, they’ll feel far less effect than they otherwise would.
Why Subutex Instead of Suboxone
Most people prescribed buprenorphine for opioid dependence receive Suboxone, which combines buprenorphine with naloxone. The naloxone component acts as a safeguard: if someone tries to inject the tablet or film to get high, the naloxone triggers immediate withdrawal, discouraging misuse. When taken under the tongue as directed, the naloxone is barely absorbed and has little effect.
Subutex contains only buprenorphine, with no naloxone. This makes it the preferred option in specific situations. The most common is pregnancy, where buprenorphine alone is recommended because the effects of naloxone on a developing baby aren’t fully established. Subutex is also typically used during the first day or two of treatment (the induction phase) before a patient switches to a combination product. Providers may also choose it for patients who have a documented sensitivity or allergic reaction to naloxone.
Starting Treatment: The Induction Phase
You can’t simply start taking buprenorphine at any time. Because it’s a partial activator of opioid receptors, taking it while full opioids are still in your system can trigger precipitated withdrawal, a sudden and intense worsening of symptoms. To avoid this, you need to be in moderate withdrawal before your first dose. Clinicians measure this using a standardized scale, and your score needs to be above a certain threshold (typically above 12 on the clinical opiate withdrawal scale) before you receive buprenorphine.
On the first day, a typical starting dose is 2 to 4 milligrams placed under the tongue. If withdrawal symptoms improve rather than worsen, another small dose follows every few hours, up to about 8 milligrams total on day one. By day two, the dose can increase in small increments toward a target of 16 milligrams daily. If precipitated withdrawal does occur, symptoms are managed and induction is reattempted the next day.
The target maintenance dose for most people is 12 to 16 milligrams per day, taken once daily. Some people need up to 24 milligrams, and in certain cases even higher doses are used with close monitoring.
How to Take Sublingual Tablets
Sublingual tablets dissolve under the tongue, and proper technique matters for the medication to absorb correctly. Place the tablets under your tongue and let them melt completely. If your dose requires more than two tablets, you can place them all at once or two at a time. Don’t chew or swallow them whole.
While the tablets dissolve, avoid eating, drinking, or talking. Once they’ve fully dissolved, take a sip of water, swish it around your teeth and gums, and swallow. Wait at least one hour before brushing your teeth. These steps help protect your tooth enamel (sublingual medications can affect dental health over time) and ensure you absorb the full dose.
Common and Serious Side Effects
The most frequent side effects affect more than 1 in 100 people and include constipation, nausea or vomiting, drowsiness, dizziness, headaches, stomach pain, and itching or skin rashes. These often improve as your body adjusts to the medication over the first few weeks.
Serious side effects are less common (fewer than 1 in 100 people) but include unexplained muscle stiffness and signs of low blood pressure like persistent dizziness, fatigue, or low energy. The most dangerous risk is respiratory depression, where breathing becomes dangerously slow and shallow. This risk is highest when buprenorphine is combined with other sedating substances like alcohol, benzodiazepines, or sleep medications. Severe allergic reactions are rare but possible, with warning signs including sudden swelling of the lips, mouth, or throat, difficulty breathing, and skin turning blue or pale.
Buprenorphine is classified as a Schedule III controlled substance, meaning it has recognized medical value but still carries some potential for dependence. Stopping it abruptly after long-term use will cause withdrawal symptoms, which is why doses are gradually tapered when treatment ends.
Use During Pregnancy
Buprenorphine is one of two first-line medications (alongside methadone) recommended for pregnant women with opioid use disorder. Both the CDC and the American College of Obstetricians and Gynecologists endorse its use in combination with behavioral therapy and medical services during pregnancy.
Babies exposed to buprenorphine in the womb may experience neonatal abstinence syndrome, a temporary withdrawal condition after birth. This is an expected and treatable outcome, and concern about it alone should not prevent treatment. Untreated opioid use disorder during pregnancy carries far greater risks, including preterm birth, low birth weight, and overdose.
After delivery, women are generally advised to continue their medication. Discontinuing buprenorphine in the period right after birth is discouraged. At minimum, treatment should continue until the baby is sleeping through the night and has finished breastfeeding.
How Long Treatment Lasts
There’s no fixed timeline for buprenorphine treatment. Some people take it for months while they stabilize their lives and build recovery skills. Others stay on it for years or indefinitely, particularly if previous attempts to taper off led to relapse. Research consistently shows that longer treatment durations are associated with better outcomes, and there’s no medical reason to rush someone off the medication if it’s working. The decision to taper is made collaboratively between you and your provider, based on how stable your recovery feels and what supports you have in place.